Chugai Pharmaceutical Co., Ltd.
General ticker "CHGCF" information:
- Sector: Health Care
- Industry: Drug Manufacturers - General
- Capitalization: $77.8B (TTM average)
Chugai Pharmaceutical Co., Ltd. follows the US Stock Market performance with the rate: 10.0%.
Estimated limits based on current volatility of 1.6%: low 60.48$, high 62.42$
Factors to consider:
- Company pays dividends (annually): last record date 2025-12-31, amount 0.94$ (Y1.52%)
- Current price 23.5% above estimated high
- Earnings for 12 months up through Q4 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [31.80$, 49.64$]
- 2025-12-31 to 2026-12-31 estimated range: [31.94$, 50.20$]
Financial Metrics affecting the CHGCF estimates:
- Negative: with PPE of 28.3 at the end of fiscal year the price was high
- Positive: Operating profit margin, % of 46.30 > 18.47
- Positive: Return on assets ratio (scaled to [-100,100]) of 14.92 > 6.13
- Positive: Industry operating profit margin (median), % of 21.15 > 9.70
- Positive: Industry earnings per price (median), % of 5.35 > 4.52
- Positive: Inventory ratio change, % of -2.73 <= -0.75
- Positive: 0.06 < Operating cash flow per share per price, % of 4.03
- Positive: 5.50 < Industry operating cash flow per share per price (median), % of 8.11
Short-term CHGCF quotes
Long-term CHGCF plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | ¥1,111,367.00MM | ¥1,170,611.00MM | ¥1,259,038.69MM |
| Operating Expenses | ¥672,193.00MM | ¥628,609.00MM | ¥668,331.69MM |
| Operating Income | ¥439,174.00MM | ¥542,002.00MM | ¥590,707.01MM |
| Non-Operating Income | ¥4,647.00MM | ¥1,032.00MM | ¥7,621.65MM |
| Interest Expense | ¥0.00MM | ¥0.00MM | ¥1,026.89MM |
| R&D Expense | ¥174,868.00MM | ¥181,440.00MM | ¥187,761.70MM |
| Income(Loss) | ¥443,821.00MM | ¥543,034.00MM | ¥598,328.65MM |
| Taxes | ¥118,349.00MM | ¥155,717.00MM | ¥163,936.93MM |
| Profit(Loss)* | ¥325,472.00MM | ¥185,088.00MM | ¥434,390.72MM |
| Stockholders Equity | ¥1,625,580.00MM | ¥1,901,499.00MM | ¥2,027,499.68MM |
| Inventory | ¥273,480.00MM | ¥240,067.00MM | ¥277,089.58MM |
| Assets | ¥1,932,547.00MM | ¥2,208,373.00MM | ¥2,470,749.13MM |
| Operating Cash Flow | ¥409,925.00MM | ¥447,600.00MM | ¥389,790.84MM |
| Capital expenditure | ¥74,258.00MM | ¥54,899.00MM | ¥76,339.56MM |
| Investing Cash Flow | ¥-37,290.00MM | ¥-227,365.00MM | ¥-205,051.77MM |
| Financing Cash Flow | ¥-139,331.00MM | ¥-141,006.00MM | ¥-307,725.29MM |
| Earnings Per Share** | ¥197.80 | ¥112.47 | ¥263.96 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.